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exchange rate fluctuations, country’s attributes modification, and drug price 
changes. Each price evaluation event implied the calculation of a new drug price 
and the model generated drug price evolution in each country over time. Model 
inputs were obtained from a literature review and consultation of representatives 
of competent authorities and international organizations. The model was validated 
by assessing actual drug prices at launch and over time for 53 randomly selected 
medicines. This model was developed for the EU Commission. Results: The model 
could be used to assess the impact of pricing policies. For example, it showed that 
the price erosion predicted under the effects of ERP only was for most products 
slower than observed in reality, and thus that price negotiations also importantly 
contributed to price erosion. It can also be used to compare alternative launch 
sequences. The simulated price trends over time were consistent with observed 
trends. ConClusions: This DES model is the first comprehensive ERP published 
model across drug life cycle that allows testing various policy scenarios and predict 
impact of ERP in the real-life. This flexible model may prove useful tool to support 
decision making from the perspective of authorities or industry.
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objeCtives: This study aimed to provide insight into the utilization of cost-effec-
tiveness modeling methods. The focus of our study was aimed at the applicability 
of these models, particularly around the major assumptions related to the clinical 
parameters used in the models, and subsequent clinical outcomes. Methods: 
MEDLINE and EMBASE were searched from 1 January 2004 to 14 February 2013 in 
order to identify published cost-effectiveness evaluations for the treatment of T2DM 
by new oral treatments (GLP-1 receptor agonists and DPP-4 inhibitors). Once iden-
tified, the articles were reviewed and grouped together according to the type of 
model and study comparators. Results: A total of 15 studies were identified in 
our review. Nearly all of the models utilized a health care payer perspective and 
provided a lifetime horizon. The CORE Diabetes Model, UKPDS Outcomes Model, 
Cardiff Diabetes Model, CDC Diabetes Cost- Effectiveness Group Model and Diabetes 
Mellitus Model were cited. Nearly all of the studies made significant assumptions 
surrounding the impact of GLP-1 receptor agonists or DPP-4 inhibitors on clinical 
parameters and subsequent short- and long-term outcomes. The impact of these 
clinical changes often resulted in large lifetime changes in health outcomes in the 
models. The validity of these projections, particularly for the longer time frames, 
is questionable. ConClusions: Future models should aim to include all relevant 
treatment outcomes, whether these relate to effects on underlying diabetes and 
its complications or to short- or long-term side effects of treatment. We need to 
explore why cost-saving interventions could benefit further from adding patient 
characteristics, which may be able to better predict the use of lower-cost alterna-
tives. Moreover, the vast array of different clinical, cost and utility data used in the 
different models reviewed makes it apparent that a uniform methodology should 
be developed for diabetes economic models.
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objeCtives: The EQ-5D-5L is a new health-state classification system consisting of 
five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/
depression), with each dimension described into five problem levels (no, slight, mod-
erate, severe, and extreme). This study aimed to estimate the time trade-off (TTO) 
values of the 3,125 EQ-5D-5L health states to urban residents in China. Methods: 
The values for 86 selected EQ-5D-5L health states were elicited using the ‘com-
posite’ TTO technique from a general population sample (n= 1,250) drawn from 5 
Chinese cities. In computer-assisted personal interviews, participants each valued 
a randomly selected block of health states (n= 10). Various function forms were con-
structed to specify the possible relationship between TTO values and health-state 
characteristics and estimated using linear regression models. The function form 
exhibiting the best fit of the data and the least prediction biases was identified to 
estimate the values of all EQ-5D-5L health states. Results: The Hausman test sug-
gested that random effects estimator was more efficient than fixed effects estimator 
for all function forms. The best model comprised a constant and twenty-one dummy 
variables indicating the presence or absence of specific problems or patterns of 
problems in a given EQ-5D-5L health state, including nineteen for all individual 
health problems except for slight anxiety/depression, one for severe or extreme 
problems in any functional dimensions, and one for the 5 mildest EQ-5D-5L health 
states. According to the final model, the mean absolute error of the predicted val-
ues for the 86 health states was 0.032 and the range of all the predicted values was 
-0.339 to 0.893. ConClusions: Values of EQ-5D-5L health states can be estimated 
using time trade-off values of a small portion of the health states. The EQ-5D-5L 
preference values estimated in this study may be used as quality-of-life weights in 
cost-utility analysis of health technologies and programs in China.
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objeCtives: In cancer, we aim at maintaining the Quality of Life (QOL) of patients. 
Yet minimal work examines predictors of QOL constructs over time. The aim of this 
study was to explore the temporal sequence leading to optimal QOL over time of key 
The inclusion of physicians’attributes is critical for discrete choice experiments. 
This study identifies some statistically significant attributes such as the referral 
process. It confirms previous results by Miele, Weiland and Dungan (2012) showing 
how patient can benefit from reduction in HbA1C with centralized referral. Further 
development investigates how significant physicians’ attributes can impact reversed 
conjoint modeling results on physicians’ cost sensitivity.
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objeCtives: The study objective was to utilize a pharmacometric model-based 
meta-analysis (PMBMA) within a health economic microsimulation model 
(HEMM) of chronic obstructive pulmonary disease (COPD). PMBMA is a type of 
meta-regression which employs non-linear models estimated on trial-level data 
to relate patient and trial characteristics, dosing, surrogate markers, and outcomes 
effects of treatment. Methods: A Markov microsimulation model was developed 
to estimate monthly changes in the key disease severity metrics of COPD (FEV1 
and exacerbations) in order to compare a hypothetical drug that increases FEV1 to 
usual care. The PMBMA was used to predict a baseline exacerbation rate in a group 
of actual trial patients, given their known baseline FEV1. The hypothetical drug 
increased baseline FEV1, thereby decreasing the exacerbation rate in the hypo-
thetical drug arm vis-à-vis the individual PMBMA predictions. Individual patient 
microsimulations and model memory allowed the rate monthly FEV1 decline to 
vary by patient and by month allowing for stochastic improvements. Validation 
of trial-level PMBMA estimates used in predictions was performed. Issues of syn-
chronizing non-COPD mortality and common random numbers in microsimulation 
models were addressed. Results: In a sample of 376 trial patients with a mean 
FEV1 (percent predicted) of 55%, had an exacerbation rate of 0.7 exacerbations per 
year, as predicted by the PMBMA. A drug that increased FEV1 at baseline by 30 mL 
resulted in a 21% decrease in exacerbations, while a 50 mL increase resulted in a 26% 
decrease. Given a simplified estimation of costs and QALYs associated with COPD, 
a drug with a 50 mL increase costing 40 Euro per month had an ICER of 46,736 Euro/
QALY. ConClusions: The synergistic aspects of PMBMA and HEMM are highlighted 
in this hypothetical example. Markov microsimulation modeling allows the finer 
predictions of PMBMA to inform parameters while individual simulations allow 
advantages of model memory.
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objeCtives: There is a trend of health economic models (HEM) becoming computa-
tionally expensive. Additionally, less complex HEMs increasingly include some type 
of computationally demanding analysis like value of information (VOI; e.g. EVPI, 
EVPPI). However, the computation time required to perform such analyses are often 
stated as the primary constraint. Our objective was to determine whether efficiency 
could be achieved using programming languages and multi-process programming 
to substantially speedup the simulation time for HEMs. Methods: Two different 
techniques were applied, firstly an implementation solely in VBA, secondly paral-
lel computing implementation in C++. The general complexity of VOI-analysis in 
HEMs algorithms is due to nested loops. Multi-process programming is suitable for 
these tasks as it decomposes complex routines into small parts which are solved 
concurrently. A publicly available hip-replacement Markov model in Excel® served 
as a blueprint. It was reconstructed using the two aforementioned techniques, both 
replicas used the spreadsheet application as the interface, but calculations were 
performed in their respective programming environments. The computational time 
required to perform the EVPPI-analysis for each one of these techniques were com-
pared. All computations were performed in an identical computational environ-
ment. Outcomes were compared to ensure there were no systematic differences in 
the underlying calculations. Results: The VBA implementation of the hip-replace-
ment model reduced simulation time by up to 7X compared to the original model. 
The improvement for the multiprocessing in C++ was 10X compared to the VBA 
implementation when running on a quad-core environment. ConClusions: This 
study demonstrated that the computation time of the selected HEM was improved 
considerably using the same language, primarily by minimizing the communication 
between VBA and spreadsheet. A more substantial improvement (~70X) was gained 
when using the multiprocessor capabilities in C++ combined with machine-level 
optimization. However, to achieve this speedup, more development time and may 
accompany reluctance due to specialist programming expertise.
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objeCtives: The objective of this project was to build a model simulating the exter-
nal reference pricing (ERP) process, applied to the 28 European Union Member States, 
Iceland, Norway and Switzerland, to understand the price dynamics of ERP-based 
systems and predict the consequences of various ERP policy scenarios. Methods: 
A discrete-event simulation (DES) modelling approach was adopted. This approach 
allowed for fixed ERP rules and quick dynamic changes. Three groups of attributes 
were included in the model: ERP policy attributes, drug attributes and countries’ 
economic attributes. Occurrences of the following events were simulated: drug 
launch and first price setting, pricing decisions using ERP in different countries, 
